INTRODUCTION {#s1}
============

Gastric cancer is one of the most common cancers worldwide, and the incidence is particularly high in Asian countries, including China \[[@R1]\]. Metastasis and recurrence are the major causes for poor prognosis in gastric cancer. Ovarian metastasis (Krukenberg tumor) is usually seen in female patients, including synchronous metastasis, and metachronous metastasis after curative resection of gastric cancer \[[@R2]\]. The reported incidence of ovarian metastasis or Krukenberg tumor is approximately 0.3% to 6.7%, however, some autopsy studies have reported incidence rates of 33% to 41% \[[@R3], [@R4]\]. Ovarian metastasis is associated with poor prognosis, and is one of the most important causes of treatment failure for gastric cancer in female patients \[[@R5]\]. Although systemic chemotherapy can provide symptom palliation and prolonged survival in patients with ovarian metastasis, the efficiency and survival time remain disappointing \[[@R2], [@R6]\]. Several studies have explored the utility of metastasectomy for Krukenberg tumors in patients with gastric cancer \[[@R7], [@R8]\] However, the role of ovarian metastasectomy is still under debate and is likely to benefit only a specific subset of patients \[[@R9]\]. So far, the optimal treatment strategy for Krukenberg tumors from gastric cancer had not been clearly established. This study was conducted to determine associations between metastasectomy of Krukenberg tumors, clinicopathological features, and survival outcome, and consequently provide optimal treatment strategy for these patients.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The median follow-up duration for all patients was 37.2 (range 2.5--71) months; median age at treatment onset was 43.4 (range 18--65) years, and mean size of metastatic ovarian tumors was 8.13 (range 2--20) cm.

Clinicopathologic characteristics of gastric cancer with synchronous or metachronous ovarian metastasis are listed in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively. Of these, tumor location, differentiation, ascites, ER and PR expression, tumor markers, and TNM stage were similar for both groups of either synchronous or metachronous ovarian metastasis.

###### Clinical characteristics of 93 patients with synchronous Krukenberg tumors

  -----------------------------------------------------------------------------------------------
  Variable                  Metastasectomy plus chemotherapy\   Chemotherapy alone\   *P*-value
                            (*n =* 49)                          (*n =* 44)            
  ------------------------- ----------------------------------- --------------------- -----------
  Median age                43.1 (26--65)                       40.9 (18--61)         0.290

  Tumor size (cm)           8.70 (2--20)                        7.33 (2.2--18)        0.119

  ECOG performance status                                                             

   0-1                      47                                  40                    0.326

   2                        2                                   4                     

  Laterality                                                                          

   Bilateral                33                                  31                    0.747

   UnilateraI               16                                  13                    

  Peritoneal metastasis                                                               

   No                       35                                  37                    0.145

   Yes                      14                                  7                     

  Signet-ring cells                                                                   

   Positive                 36                                  29                    0.427

   Negative                 13                                  15                    

  Differentiation                                                                     

   Well and moderately      8                                   4                     0.299

   Poorly                   41                                  40                    

  Ascites                                                                             

   No                       20                                  11                    0.106

   Yes                      29                                  33                    

  ER                                                                                  

   Positive                 22                                  14                    0.196

   Negative                 27                                  30                    

  PR                                                                                  

   Positive                 16                                  8                     0.111

   Negative                 33                                  36                    

  Serum CEA (ng/mL)                                                                   

   Normal                   40                                  36                    0.982

   \>5                      9                                   8                     

  Serum CA19-9 (U/mL)                                                                 

   Normal                   33                                  26                    0.409

   \>39                     16                                  18                    

  Serum CA125 (U/mL)                                                                  

   Normal                   20                                  14                    0.368

   \>35                     29                                  30                    
  -----------------------------------------------------------------------------------------------

###### Clinical characteristics of 59 patients with metachronous Krukenberg tumors

  -----------------------------------------------------------------------------------------------
  Variable                  Metastasectomy plus chemotherapy\   Chemotherapy alone\   *P*-value
                            (*n =* 40)                          (*n =* 19)            
  ------------------------- ----------------------------------- --------------------- -----------
  Median age                46.9 (31--62)                       42.7 (20--60)         0.128

  Tumor size (cm)           8.78 (4.3--20)                      7.73 (4.5--16.7)      0.261

  ECOG performance status                                                             

   0-1                      39                                  17                    0.190

   2                        1                                   2                     

  Laterality                                                                          

   Bilateral                32                                  16                    0.700

   UnilateraI               8                                   3                     

  Peritoneal metastasis                                                               

   No                       29                                  15                    0.595

   Yes                      11                                  4                     

  Signet-ring cells                                                                   

   Positive                 31                                  16                    0.550

   Negative                 9                                   3                     

  Differentiation                                                                     

   Well and moderately      6                                   4                     0.563

   Poorly                   34                                  15                    

  AJCC stage                                                                          

   I--II                    5                                   1                     0.390

   III--IV                  35                                  18                    

  Ascites                                                                             

   No                       9                                   5                     0.748

   Yes                      31                                  14                    

  ER                                                                                  

   Positive                 17                                  8                     0.977

   Negative                 23                                  11                    

  PR                                                                                  

   Positive                 13                                  6                     

   Negative                 27                                  13                    0.944

  Serum CEA (ng/mL)                                                                   

   Normal                   33                                  16                    0.870

   \>5                      7                                   3                     

  Serum CA19-9 (U/mL)                                                                 

   Normal                   31                                  13                    0.454

   \>39                     9                                   6                     

  Serum CA125 (U/mL)                                                                  

   Normal                   21                                  7                     0.260

   \>35                     19                                  12                    
  -----------------------------------------------------------------------------------------------

Treatment outcome and prognostic factors {#s2_2}
----------------------------------------

The median OS of patients with synchronous ovarian metastasis was 15.6 months (95% confidence interval \[CI\], 13.9 to 17.3 months). The median OS of metastasectomy group and non-metastasectomy group was 19.0 months (95% CI,16.6 to 21.5 months) and 11.8 months (95% CI, 10.1 to 13.5months), respectively. For patients with metachronous ovarian metastasis, median OS was 21.7 (95% CI 17.6--25.9) months. The median OS of metastasectomy group and non-metastasectomy group was 24.6months (95% CI,19.3 to 30.0 months) and 14.3 months (95% CI, 10.8 to 17.8months), respectively. Therefore, patients in the metastasectomy group had a significantly better OS than patients in the non-metastasectomy group (synchronous ovarian metastasis: P \< 0.001, Figure [1](#F1){ref-type="fig"}; metachronous ovarian metastasis: P = 0.02, Figure [2](#F2){ref-type="fig"}).

![Kaplan--Meier analysis of overall survival in patients with or without metastasectomy of synchronous Krukenberg tumors](oncotarget-08-82558-g001){#F1}

![Kaplan--Meier analysis of overall survival in patients with or without metastasectomy of metachronous Krukenberg tumors](oncotarget-08-82558-g002){#F2}

Based on univariate analysis, metastasectomy, peritoneal carcinomatosis, signet ring cell, ascites, expression of ER-β and PR, and serum levels of CA19-9 (\>37 U/mL) were prognostic factors associated with survival. After adjusting covariates on multivariate analysis, metastasectomy (hazard ration \[HR\] 0.486; 95% CI 0.323--0.729; *P* \< 0.001), presence of peritoneal carcinomatosis (HR 1.934; 95% CI 1.230--3.049; *P* = 0.004), ER-β positivity (HR 0.404; 95% CI 0.251--0.648; *P* \< 0.001), and PR positivity (HR 0.496; 95% CI 0.301--0.817; *P* \< 0.001) were independent predictors of OS (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate analysis of overall survival

  Variable                       Univariate             Multivariate                          
  ------------------------------ ---------------------- -------------- ---------------------- ---------
  Age (≥50 years)                0.712 (0.445--1.139)   0.156          \-                     \-
  Size of tumor (\<5 cm)         0.736 (0.491--1.104)   0.139          \-                     \-
  Bilateral ovarian metastases   0.775 (0.515--1.165)   0.220          \-                     \-
  Metastasectomy                 0.467 (0.318--0.685)   \<0.001        0.486 (0.323--0.729)   \<0.001
  Peritoneal carcinomatosis      2.359 (1.585--3.512)   \<0.001        1.934 (1.230--3.049)   0.004
  Signet-ring cells              1.871 (1.272--2.751)   0.001          1.183 (0.778--1.802)   0.430
  Ascites                        1.968 (1.269--3.051)   0.002          1.450 (0.914--2.294)   0.114
  Gastrectomy                    0.761 (0.520--1.114)   0.160          \-                     \-
  ER positive                    0.254 (0.166--0.389)   \<0.001        0.404 (0.251--0.648)   \<0.001
  PR positive                    0.376 (0.238--0.596)   \<0.001        0.496 (0.301--0.817)   \<0.001
  CA125                          1.427 (0.939--2.170)   0.096          \-                     \-
  CEA                            1.369 (0.873--2.146)   0.171          \-                     \-
  CA199                          1.628 (1.108--2.393)   0.013          1.447 (0.963--2.179)   0.075

Additionally, 63.3% (57/90) of the patients had R0 resection. Median OS was 30.5 (95% CI 25.1--35.9) months in the R0 resection group and 12.2 (95% CI 10.4--14.0) months in the non-R0 resection groups. Survival was superior in the R0 resection group as compared to the non-R0 resection groups (*P* \< 0.001; Figure [3](#F3){ref-type="fig"}).

![Kaplan--Meier analysis of overall survival in patients with or without R0 resection](oncotarget-08-82558-g003){#F3}

Correlation between expression of sex hormone receptors, clinicopathologic factors, and survival {#s2_3}
------------------------------------------------------------------------------------------------

The positive rate of ER-β and PR was 44.7% and 31.6%.However, ER-α showed no positivity in any gastric cancer tissue sample.

The positive/negative expression profiles of representative sex hormone receptors are shown in Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}. Uni- and multivariate analyses showed a positive correlation between expression of ER-β and PR and better survival. The average OS in ER-β-positive and -negative patients was 24.4 (95% CI 21.5--27.4) months and 12.6 (95% CI 10.8--14.4) months, respectively (*P* \< 0.001; Figure [6](#F6){ref-type="fig"}). Average OS in PR-positive and -negative patients was 23.7 (95% CI 20.2--27.3) months and 15.4 (95% CI 13.2--17.5) months, respectively (*P* \< 0.001; Figure [7](#F7){ref-type="fig"}). These results indicate that expression of ER-β or PR are favorably associated with better prognosis in patients with ovarian metastases from a primary gastric cancer.

###### A representative image of negative (4-1) or positive (4-2) ER-β expression

![](oncotarget-08-82558-g004-1)

![](oncotarget-08-82558-g004-2)

###### A representative image of negative (5-1) or positive (5-2) PR expression
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![Survival curves of patients with positive or negative expression of ER-β](oncotarget-08-82558-g006){#F6}

![Survival curves of patients with positive or negative expression of PR](oncotarget-08-82558-g007){#F7}

Furthermore, we evaluated the relationship between the expression of ER-β, PR, and clinicopathologic factors, and found negative expression of ER-β to be significantly associated with peritoneal metastasis, signet-ring cells, and ascites; negative expression of PR was significantly associated with laterality as well as peritoneal metastasis \[Table [4](#T4){ref-type="table"}\]. On multivariate analysis, peritoneal metastasis was significantly associated with negative expression of ER-β and PR. In addition, laterality was also significantly associated with negative expression of PR.

###### Correlation between ER-β and PR expressions and clinicopathologic characteristics.

                          ER-β   PR                       
  ----------------------- ------ ---- --------- ---- ---- -------
  Age (years)                                             
   ≥50                    16     22   0.706     16   22   0.107
   \<50                   52     62             32   82   
  Tumor size (cm)                                         
   ≥5                     48     58   0.837     38   68   0.086
   \<5                    20     26             10   36   
  Laterality                                              
   Bilateral              50     57   0.446     41   67   0.008
   UnilateraI             18     27             7    37   
  Peritoneal metastasis                                   
   No                     57     44   \<0.001   40   61   0.003
   Yes                    11     40             8    43   
  Signet-ring cells                                       
   Positive               26     46   0.042     21   51   0.544
   Negative               42     38             27   53   
  Ascites                                                 
   No                     30     23   0.031     19   34   0.407
   Yes                    38     61             29   70   
  Ovarian metastases                                      
   Synchronous            41     52   0.839     28   65   0.624
   Metachronous           27     32             20   39   
  Serum CEA (ng/mL)                                       
   Normal                 58     61   0.059     38   81   0.859
   \>5                    10     23             10   23   
  Serum CA19-9 (U/mL)                                     
   Normal                 43     53   0.986     31   65   0.805
   \>39                   25     31             17   39   
  Serum CA125 (U/mL)                                      
   Normal                 27     25   0.199     14   38   0.373
   \>35                   41     59             34   66   

Chemotherapy regimens and toxicity {#s2_4}
----------------------------------

Paclitaxel and S-1 were the most frequently used chemotherapeutic drugs. Median chemotherapy duration was longer in the metachronous group (4.5 cycles, range 3--8 cycles) as compared to the synchronous group (3.7 cycles, range 1--7 cycles) although the difference was not statistically significant (*P* \> 0.05). Drug-related adverse events and grade 3 or 4 toxicity occurred in 67.1% (102/152) and 37.5% (57/152) of patients, respectively. The most common grade 3 or 4 hematological toxic effects were leucopenia/neutropenia(26.3%) and thrombocytopenia(7.9%); the most common grade 3 or 4 nonhematological toxic effects were elevated serum aspartate aminotransferase levels (4.6%) and rash (2.6%).

Postoperative complications {#s2_5}
---------------------------

Fifteen patients (16.9%) developed postoperative complications, including anastomotic leakage (*n* = 5), abdominal abscesses (*n* = 4), delayed gastric emptying (*n* = 4), pneumonia (*n* = 2), and bleeding (*n* = 1).Most of these patients were conservatively managed with a successful outcome, but reoperation was necessary in one patient due to intra-abdominal bleeding.

DISCUSSION {#s3}
==========

Cancers of the gastrointestinal tract are most likely to generate ovarian metastases in female patients and this is one of the most important causes of treatment failure \[[@R11]\]. The prognosis of patients with gastric cancer and metastasis to the ovaries has been reported to be poorer, as compared with prognosis in other primary gastrointestinal tumors \[[@R12]\]. In the past, chemotherapy was the main treatment for gastric cancer with ovarian metastasis, but the efficiency was disappointing, with a median survival time of 7 to 11 months \[[@R13]\]. Some retrospective study reports in recent years indicated that metastasectomy of Krukenberg tumors could improve prognosis of these patients \[[@R7], [@R8], [@R9]\]. However, an optimal therapeutic strategy for Krukenberg tumors from gastric cancer has not been fully established.

Lu et al. retrospectively reviewed a series of 85 patients diagnosed with advanced gastric cancer together with Krukenberg tumor between 2000 and 2010, and reported a median survival time of 14.1 months in the resection group as compared to 8 months in the nonresection group \[[@R7]\]. In another paper, Cho et al. reported that OS differed significantly between patients undergoing metastasectomy plus chemotherapy and those undergoing chemotherapy alone (18.0 months vs. 8.0 months in patients with stage IV gastric cancer; 19.0 months vs. 9.0 months in patients with recurrent Krukenberg tumors).Nevertheless, the imbalance between the two groups should cast some doubts on the significance of the findings \[[@R8]\].

In the present study, we retrospectively analyzed outcomes of 152 patients with synchronous and metachronous ovarian metastasis. Metastasectomy, relative to non-metastasectomy treatment, resulted in significantly better OS in patients with synchronous (19.0 months vs. 13.5 months; *P* \< 0.001) and metachronous (24.6 months vs. 14.3 months; *P* = 0.02) ovarian metastasis. The present series included a large study sample, with similar clinicopathologic characteristics for both study groups. Our results are in accordance with those reported in the earlier literature, therefore, we can conclude that metastasectomy should be recommended in patients with ovarian metastasis.

Analysis of prognostic factors can, moreover, facilitate identification of patients most likely to benefit from treatment. Metastasectomy, peritoneal carcinomatosis, and expression of ER-β and PR were independent predictors of OS. Krukenberg tumors are often associated with different degrees of peritoneal metastasis, which frequently induces ascites, intestinal obstruction, or hydronephrosis and seriously impair patient quality of life \[[@R14]\]. There is currently no standard treatment for ovarian metastasis when it presents with peritoneal metastases from gastric cancer, however, cytoreductive surgery in combination with chemotherapy could offer a survival advantage for these patients \[[@R15], [@R16]\]. In our study, limited peritoneal metastases were resected in a metastasectomy, and this was followed by systemic chemotherapy. Subgroup analysis showed that the survival of the R0 resection group was superior to that of the non-R0 resection group. Therefore, surgical resection without gross residual disease may improve prognosis in patients with Krukenberg tumors. Chemotherapy is another main treatment for these patients, and improves quality of life and OS \[[@R17]\]. Several chemotherapeutic agents are effective against Krukenberg tumors with peritoneal metastasis, including fluoropyrimidine, platinum, taxanes, and epirubicin, either alone or in combination \[[@R18], [@R19]\]. A European study reported encouraging results from the use of hyperthermic intraperitoneal chemotherapy (HIPEC) \[[@R5]\], but these need to be validated in future research.

Some studies have reported a correlation between expression of sex hormone receptors and the incidence and progression of gastric cancer \[[@R20]\]. It has been suggested that sex hormones play critical protective roles in female patients with gastric cancer \[[@R21], [@R22]\]. Recently, a meta-analysis suggested that longer exposure to the effects of estrogen may potentially decrease the risk of gastric cancer \[[@R23]\]. However, the presence and role of sex hormone receptors in Krukenberg tumors were undetermined. We evaluated the expression of ER-a, ER-β, and PR in gastric cancer specimens, and found that only ER-β and PR were detected. Our data showed that positive expression of ER-β or PR were favorably associated with better prognosis of gastric cancer patients with ovarian metastases. From our results and those reported in the related literature, ER and PR play an important role in the etiopathogenesis of Krukenberg tumors. However, some issues remain to be resolved. It is unclear whether targeted therapy of sex hormone receptors can lower the incidence of ovarian metastasis from ER- or PR-positive gastric cancer. Moreover, the possibility of ER or PR expression being used as a reliable indicator of prophylactic ovariectomy is worth exploring. Thus, future studies investigating the significance of ER or PR expression in carcinogenesis and tumor progression of gastric cancer and Krukenberg tumor are necessary.

Our study had certain limitations because it was a retrospective analysis, and several confounding factors may have influenced our findings. However, the fact that it reports results from a large series of patients and presents the first evaluation of the role of sex hormone receptors in Krukenberg tumors from gastric cancer. The results are expected to provide useful information for formulating treatment strategies for those patients.

The present study demonstrated that the metastasectomy in combination with chemotherapy was associated with survival benefits in patients with synchronous or metachronous Krukenberg tumors from gastric cancer. Metastasectomy, peritoneal carcinomatosis, and ER-β and PR expression status were prognostic factors for survival. Well-designed prospective studies are needed to confirm these results, and will be important in developing optimal treatment strategies for Krukenberg tumors of gastric origin.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

From January 2005 to December 2014, 4381 female gastric cancer patients were admitted and treated at the Zhejiang Cancer Hospital. Among these patients, 152 with krukenberg tumor detected by the imaging studies or by pathological evaluation of the metastasectomy specimens were retrospectively reviewed. Patient demographics, radiological details, surgical data, pathological features, and survival were collected and analyzed. Outpatient records combined with telephone interviews were used for follow-up. All the patients suspected of having Krukenberg tumor underwent imaging studies to identify the extent of disease and resectability. The patients included in this study were initially regarded as having resectable diseases. Therefore, a resection was only performed in case of Krukenberg tumor without or with limited peritoneal dissemination. At the completion of surgery, the residual disease state of each patient was recorded according to the presence or absence of gross residual disease, which was classified as negative resection margins (R0), microscopic tumor infiltration (R1), and macroscopic residual tumor (R2).

Overall, 93 patients were initially diagnosed as synchronous metastasis and 59 as metachronous metastasis after they underwent curative resection of gastric cancer. Patients were divided into two groups according to treatment modality: the metastasectomy group( received both chemotherapy and metastasectomy for Krukenberg tumor) and the non-metastasectomy group(received chemotherapy alone). Overall survival (OS) of patients with synchronous ovarian metastasiswas defined as duration from the date of pathologic diagnosis of gastric cancer to the date of death or last follow-up. OS of patients with metachronous ovarian metastasis was defined as duration from the date of radiologic diagnosis of Krukenberg tumor to the date of death or last follow-up. For both groups, December 31, 2016 was the cutoff date for OS.

Detection of sex hormone receptors in gastric cancer specimens {#s4_2}
--------------------------------------------------------------

The expression of estrogen receptor (ER)-α,ER-β, and progesterone receptor (PR) in gastric cancer, which may potentially be related to the ovarian metastasis, was detected by immunohistochemistry (IHC) using the Novolink Polymer Detection System as described previously \[[@R10]\]. The following primary antibodies were used: ER-α (ab37438, dilution 1:200; Abcam, Cambridge, UK), ER-β (ab288, dilution 1:100; Abcam), and PR (ab16661, dilution 1:100; Abcam). All specimens were independently evaluated by two pathologists who were blinded to study grouping. Samples where more than 10% of the tumor cells were stained were regarded as positive.

Ethics statement {#s4_3}
----------------

The study was approved by the institutional ethics review board of Zhejiang Cancer Hospital. Written informed consent was obtained from all study participants. All study procedures were undertaken in accordance with the principles of the Declaration of Helsinki and relevant human research policies in China.

Statistical analysis {#s4_4}
--------------------

For continuous variables, two-tailed Student *t*-tests were used to compare demographic and clinical characteristics between the study groups. For discrete variables, a chi-square test was used. Kaplan--Meier analysis was used to calculate survival, and log-rank test was performed to compare OS between treatment groups. Independent prognostic factors were determined by multivariate analysis using the Cox proportional hazards model. All statistical analyses were conducted on SPSS 19.0 for Windows (IBM Corporation, Armonk, NY, USA). A *P* value less than 0.05 was considered indicative of statistical significance.

We express our appreciation to Professor Ahmed O. Kaseb (Gastrointestinal Medical Oncology, M. D. Anderson Cancer Center) who has offered many valuable comments and suggestions.

**Author contributions**

Pengfei Yu, Litao Yang, Gaiguo Dai, Jieer Ying, Yian Du: Concept and design of study; Ling Huang, Guoping Cheng,:analysis and interpretation of data; Pengfei Yu, Ling Huang and Yian Du, Drafting the article; Pengfei Yu and Yian Du :Final approval of the version to be published.

**CONFLICTS OF INTEREST**

The authors declare no competing interests.

**FUNDING**

This study was supported by Natural Science Foundation of Zhejiang Province of China (No.LY14H160007) and "1022 Talent Plan" of Zhejiang Cancer Hospital.

OS

:   overall survival

HIPEC

:   hyperthermic intraperitoneal chemotherapy

ER

:   estrogen receptor

PR

:   progesterone receptor

IHC

:   immunohistochemistry
